Boan Biology independently developed the drug Dulaglutide Injection, which has been approved for market launch.

Boan Biotechnology announced on the Hong Kong Stock Exchange that its independently developed BoYouping has obtained market approval from the National Medical Products Administration for blood sugar control in adult type 2 diabetes patients. BoYouping is a long-acting GLP-1 receptor agonist, and its commercialization in mainland China is carried out through a partnership between the company and Shing Pharma Holdings.